Barclays analyst David E. Strauss maintained a Buy rating on Leidos Holdings (LDOS – Research Report) on May 3 and set a price target of $160.00. The company’s shares closed last Friday at $141.67.
According to TipRanks, E. Strauss is a 4-star analyst with an average return of 6.4% and a 59.18% success rate. E. Strauss covers the Industrials sector, focusing on stocks such as Boeing, GE Aerospace, and Spirit AeroSystems.
Currently, the analyst consensus on Leidos Holdings is a Strong Buy with an average price target of $153.08, which is an 8.05% upside from current levels. In a report released on May 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $160.00 price target.
The company has a one-year high of $143.35 and a one-year low of $75.47. Currently, Leidos Holdings has an average volume of 989.5K.
Based on the recent corporate insider activity of 138 insiders, corporate insider sentiment is neutral on the stock. Most recently, in February 2024, Noel Williams, a Director at LDOS bought 4,788.00 shares for a total of $252,327.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leidos Holdings (LDOS) Company Description:
Leidos Holdings, Inc. is a holding company, which engages in the provision of scientific, engineering and information technology services and solutions in the areas of defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment focuses on deploying agile, cost-effective solutions to meet the ever-changing missions of the company’s customers in areas of intelligence surveillance and reconnaissance, enterprise IT and integrated systems and cybersecurity and global services. The Civil segment focuses on seamlessly integrating and protecting physical, digital and data domains. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.
Read More on LDOS:
- Jefferies aerospace/defense analyst to hold analyst/industry conference call
- Leidos price target raised to $165 from $150 at Truist
- Leidos price target raised to $140 from $120 at RBC Capital
- Leidos awarded $206M NGA mission software modernization contract
- Leidos price target raised to $155 from $140 at TD Cowen
